Invention Grant
- Patent Title: Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
-
Application No.: US16543832Application Date: 2019-08-19
-
Publication No.: US11059896B2Publication Date: 2021-07-13
- Inventor: Daniel B. Dix , Xiaolin Tang
- Applicant: Regeneron Pharmaceuticals, Inc.
- Applicant Address: US NY Tarrytown
- Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee Address: US NY Tarrytown
- Agency: Schwabe, Williamson & Wyatt PC
- Agent Lisa Dombach Flanagan
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K9/00 ; A61K47/18 ; A61K39/395 ; A61M5/315
Abstract:
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Information query
